The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 4
- 4 renewals
- Median first-year cost
- $999,517
- $3,997,694 in all
- Institutions
- 4
- 4 contact PIs
- Patents
- 2
- from 2 funded projects
Awards by fiscal year
Fiscal years 2014 to 2026.
Most frequent institutions
- ARONORA, INC.1
- ELEX BIOTECH, LLC1
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC1
- TRANSMURAL SYSTEMS, LLC1
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-S (F1))2
- Special Emphasis Panel (ZHL1 CSR-A (F1))1
- Special Emphasis Panel (ZHL1 CSR-Q (F2))1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2021 | Phase IIB Transmural Systems Transcatheter Cavopulmonary Bypass Endograft2R44HL147361-02A1 | Rafiee, Nasser | TRANSMURAL SYSTEMS, LLC, MA | First-year cost $998,716 | Study section ZHL1 |
| FY2020 | Factor XII Inhibitor for Surface Initiated Thrombosis2R44HL126235-04A1 | Lorentz, Christina UTucker, Erik Ian | ARONORA, INC., OR | First-year cost $999,930 | Study section ZHL1 |
| FY2019 | Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT2R44HL123126-04 | Wrobel, Jay Edward | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | First-year cost $999,945 | Study section ZHL1 |
| FY2019 | Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT2R44HL114206-04 | Kawahara, Douglas J | ELEX BIOTECH, LLC, OR | First-year cost $999,103 | Study section ZHL1 |
Patents from its funded projects
2 patents name 2 of the 4 funded projects.
- US 12,134,657 (opens the patent at USPTO, a PDF, in a new tab)THERAPEUTIC FACTOR XII ANTIBODYGranted November 5, 2024 to Oregon Health & Science University and Aronora, Inc.R44HL126235 · ARONORA, INC., OR
- US 11,427,542 (opens the patent at USPTO, a PDF, in a new tab)Compounds for treatment of cardiac arrhythmias and heart failureGranted August 30, 2022 to Elex Biotech, Inc.R44HL114206 · ELEX BIOTECH, LLC, OR
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-14-0.3.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.